{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T13:51:01Z","timestamp":1781877061594,"version":"3.54.5"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2026,1,14]],"date-time":"2026-01-14T00:00:00Z","timestamp":1768348800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,1,14]],"date-time":"2026-01-14T00:00:00Z","timestamp":1768348800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100002839","name":"Charit\u00e9 - Universit\u00e4tsmedizin Berlin","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100002839","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Transl Oncol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Adenocarcinoma of the esophageal junction and stomach (AEG\/S) remains one of the deadliest cancers worldwide. New treatment options are urgently needed. A new target could be trophoblast cell surface protein 2 (TROP2), which is expressed in a variety of solid tumors and can be targeted, e.g., by sacituzumab govitecan, which has shown promising results in triple-negative breast cancer. This study investigates the expression of TROP2 in patients with AEG\/S and correlates its expression with clinical and histopathological endpoints.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>TROP2 expression was assessed in a cohort of 250 patients who underwent primary surgery for AEG\/S. Immunohistochemistry was performed on tissue microarrays constructed from primary tumors and lymph node metastases to quantify TROP2 expression intensity. Clinical variables, including overall survival and patient demographics, as well as tumor-specific characteristics such as stage and grade, were correlated with TROP2 expression to evaluate its potential prognostic relevance in AEG\/S.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      TROP2 was expressed in 86% of primary tumors and 81.3% of lymph node metastases. The intensity of TROP2 expression (low vs. medium vs. high) was correlated negatively with overall survival (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.05, 70.9 months vs. 54.2 months vs. 39.5 months), lymphatic invasion (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.05,\n                      <jats:italic>V<\/jats:italic>\n                      \u2009=\u20090.138), and higher grading (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.037,\n                      <jats:italic>V<\/jats:italic>\n                      \u2009=\u20090.143). The intensity of TROP2 expression in lymph node metastases and primary tumors correlated significantly (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001,\n                      <jats:italic>\u03c1<\/jats:italic>\n                      \u2009=\u20090.444). There was a non-significant increase in positive lymphonodal status (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.093,\n                      <jats:italic>V<\/jats:italic>\n                      \u2009=\u20090.138) in patients with higher TROP2 expression.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>In Caucasian AEG\/S patients, TROP2 is expressed in the majority of cases. TROP2 expression intensity itself has an impact on survival, which could be explained by a more aggressive phenotype, which leads to lymphatic invasion and lymph node metastasis.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s12094-025-04203-6","type":"journal-article","created":{"date-parts":[[2026,1,14]],"date-time":"2026-01-14T11:28:50Z","timestamp":1768390130000},"page":"2959-2966","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Prognostic impact of TROP2 in adenocarcinoma of the esophageal junction and stomach"],"prefix":"10.1007","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0009-0006-2184-5282","authenticated-orcid":false,"given":"Anselm","family":"Pittrof","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Arnold","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Severin","family":"Daum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonas","family":"Staudacher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erika","family":"Berg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Hummel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Horst","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beate","family":"Rau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulrike","family":"Stein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa Marie","family":"Eich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph","family":"Treese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,14]]},"reference":[{"key":"4203_CR1","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3322\/caac.21834","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74:229\u201363. https:\/\/doi.org\/10.3322\/caac.21834.","journal-title":"CA Cancer J Clin"},{"key":"4203_CR2","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1016\/S0140-6736(10)61121-X","volume":"376","author":"Y-J Bang","year":"2010","unstructured":"Bang Y-J, Cutsem EV, Feyereislova A, Chung HC, Shen L, Sawaki A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet. 2010;376:687\u201397. https:\/\/doi.org\/10.1016\/S0140-6736(10)61121-X.","journal-title":"Lancet"},{"key":"4203_CR3","doi-asserted-by":"publisher","first-page":"1224","DOI":"10.1016\/S1470-2045(14)70420-6","volume":"15","author":"H Wilke","year":"2014","unstructured":"Wilke H, Muro K, Van Cutsem E, Oh S-C, Bodoky G, Shimada Y, et al. Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial. Lancet Oncol. 2014;15:1224\u201335. https:\/\/doi.org\/10.1016\/S1470-2045(14)70420-6.","journal-title":"Lancet Oncol"},{"key":"4203_CR4","doi-asserted-by":"publisher","first-page":"4036","DOI":"10.1200\/JCO.2024.42.16_suppl.4036","volume":"42","author":"K Shitara","year":"2024","unstructured":"Shitara K, Van Cutsem E, Lordick F, Enzinger PC, Ilson DH, Shah MA, et al. Final overall survival results from phase 3 SPOTLIGHT study evaluating zolbetuximab + mFOLFOX6 as first-line (1L) treatment for patients (Pts) with claudin 18 isoform 2 (CLDN18.2)+, HER2\u2212, locally advanced (LA) unresectable or metastatic gastric or gastroesophageal junction (mG\/GEJ) adenocarcinoma. J Clin Oncol. 2024;42:4036\u20134036. https:\/\/doi.org\/10.1200\/JCO.2024.42.16_suppl.4036.","journal-title":"J Clin Oncol"},{"key":"4203_CR5","doi-asserted-by":"publisher","first-page":"2357","DOI":"10.1007\/s12094-020-02380-0","volume":"22","author":"A Arnold","year":"2020","unstructured":"Arnold A, Daum S, von Winterfeld M, Berg E, Hummel M, Rau B, et al. Prognostic impact of claudin 18.2 in gastric and esophageal adenocarcinomas. Clin Transl Oncol. 2020;22:2357\u201363. https:\/\/doi.org\/10.1007\/s12094-020-02380-0.","journal-title":"Clin Transl Oncol"},{"key":"4203_CR6","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1016\/S1470-2045(23)00515-6","volume":"24","author":"SY Rha","year":"2023","unstructured":"Rha SY, Oh D-Y, Ya\u00f1ez P, Bai Y, Ryu M-H, Lee J, et al. Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for HER2-negative advanced gastric cancer (KEYNOTE-859): a multicentre, randomised, double-blind, phase 3 trial. Lancet Oncol. 2023;24:1181\u201395. https:\/\/doi.org\/10.1016\/S1470-2045(23)00515-6.","journal-title":"Lancet Oncol"},{"key":"4203_CR7","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1200\/JCO.22.02867","volume":"42","author":"B Rau","year":"2024","unstructured":"Rau B, Lang H, Koenigsrainer A, Gockel I, Rau H-G, Seeliger H, et al. Effect of hyperthermic intraperitoneal chemotherapy on cytoreductive surgery in gastric cancer with synchronous peritoneal metastases: the phase III GASTRIPEC-I trial. J Clin Oncol. 2024;42:146\u201356. https:\/\/doi.org\/10.1200\/JCO.22.02867.","journal-title":"J Clin Oncol"},{"key":"4203_CR8","doi-asserted-by":"publisher","first-page":"28989","DOI":"10.18632\/oncotarget.25615","volume":"9","author":"DM Goldenberg","year":"2018","unstructured":"Goldenberg DM, Stein R, Sharkey RM. The emergence of trophoblast cell-surface antigen 2 (TROP-2) as a novel cancer target. Oncotarget. 2018;9:28989\u20139006. https:\/\/doi.org\/10.18632\/oncotarget.25615.","journal-title":"Oncotarget"},{"key":"4203_CR9","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15061744","volume":"15","author":"P Lombardi","year":"2023","unstructured":"Lombardi P, Filetti M, Falcone R, Altamura V, Paroni Sterbini F, Bria E, et al. Overview of Trop-2 in cancer: from pre-clinical studies to future directions in clinical settings. Cancers. 2023;15:1744. https:\/\/doi.org\/10.3390\/cancers15061744.","journal-title":"Cancers"},{"key":"4203_CR10","doi-asserted-by":"publisher","first-page":"3870","DOI":"10.1158\/1078-0432.CCR-14-3321","volume":"21","author":"AN Starodub","year":"2015","unstructured":"Starodub AN, Ocean AJ, Shah MA, Guarino MJ, Picozzi VJ Jr., Vahdat LT, et al. First-in-human trial of a novel anti-Trop-2 antibody-SN-38 conjugate, sacituzumab govitecan, for the treatment of diverse metastatic solid tumors. Clin Cancer Res. 2015;21:3870\u20138. https:\/\/doi.org\/10.1158\/1078-0432.CCR-14-3321.","journal-title":"Clin Cancer Res"},{"key":"4203_CR11","doi-asserted-by":"publisher","DOI":"10.3390\/molecules26237294","volume":"26","author":"G Pavone","year":"2021","unstructured":"Pavone G, Motta L, Martorana F, Motta G, Vigneri P. A new kid on the block: sacituzumab govitecan for the treatment of breast cancer and other solid tumors. Molecules. 2021;26:7294. https:\/\/doi.org\/10.3390\/molecules26237294.","journal-title":"Molecules"},{"key":"4203_CR12","doi-asserted-by":"publisher","first-page":"1529","DOI":"10.1056\/NEJMoa2028485","volume":"384","author":"A Bardia","year":"2021","unstructured":"Bardia A, Hurvitz SA, Tolaney SM, Loirat D, Punie K, Oliveira M, et al. Sacituzumab govitecan in metastatic triple-negative breast cancer. N Engl J Med. 2021;384:1529\u201341. https:\/\/doi.org\/10.1056\/NEJMoa2028485.","journal-title":"N Engl J Med"},{"key":"4203_CR13","doi-asserted-by":"publisher","first-page":"746","DOI":"10.1016\/j.annonc.2021.03.005","volume":"32","author":"A Bardia","year":"2021","unstructured":"Bardia A, Messersmith WA, Kio EA, Berlin JD, Vahdat L, Masters GA, et al. Sacituzumab govitecan, a Trop-2-directed antibody-drug conjugate, for patients with epithelial cancer: final safety and efficacy results from the phase I\/II IMMU-132-01 basket trial. Ann Oncol. 2021;32:746\u201356. https:\/\/doi.org\/10.1016\/j.annonc.2021.03.005.","journal-title":"Ann Oncol"},{"key":"4203_CR14","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1159\/000522206","volume":"89","author":"D Dum","year":"2022","unstructured":"Dum D, Taherpour N, Menz A, H\u00f6flmayer D, V\u00f6lkel C, Hinsch A, et al. Trophoblast cell surface antigen 2 expression in human tumors: a tissue microarray study on 18,563 tumors. Pathobiology. 2022;89:245\u201358. https:\/\/doi.org\/10.1159\/000522206.","journal-title":"Pathobiology"},{"key":"4203_CR15","doi-asserted-by":"publisher","first-page":"6136","DOI":"10.18632\/oncotarget.6733","volume":"7","author":"W Zhao","year":"2016","unstructured":"Zhao W, Zhu H, Zhang S, Yong H, Wang W, Zhou Y, et al. Trop2 is overexpressed in gastric cancer and predicts poor prognosis. Oncotarget. 2016;7:6136\u201345. https:\/\/doi.org\/10.18632\/oncotarget.6733.","journal-title":"Oncotarget"},{"key":"4203_CR16","doi-asserted-by":"publisher","first-page":"4789","DOI":"10.3390\/cancers14194789","volume":"14","author":"S Hoppe","year":"2022","unstructured":"Hoppe S, Meder L, Gebauer F, Ullrich RT, Zander T, Hillmer AM, et al. Trophoblast cell surface antigen 2 (TROP2) as a predictive bio-marker for the therapeutic efficacy of sacituzumab govitecan in adenocarcinoma of the esophagus. Cancers. 2022;14:4789. https:\/\/doi.org\/10.3390\/cancers14194789.","journal-title":"Cancers"},{"key":"4203_CR17","doi-asserted-by":"publisher","DOI":"10.1016\/j.prp.2019.152662","volume":"215","author":"A Arnold","year":"2019","unstructured":"Arnold A, Daum S, von Winterfeld M, Berg E, Hummel M, Horst D, et al. Analysis of NTRK expression in gastric and esophageal adenocarcinoma (AGE) with pan-TRK immunohistochemistry. Pathol Res Pract. 2019;215:152662. https:\/\/doi.org\/10.1016\/j.prp.2019.152662.","journal-title":"Pathol Res Pract"},{"key":"4203_CR18","doi-asserted-by":"publisher","DOI":"10.1016\/j.prp.2024.155724","volume":"264","author":"MR Van Bockstal","year":"2024","unstructured":"Van Bockstal MR, Depelsemaeker M-C, Daoud L, Fontanges Q, Francois A, Guiot Y, et al. Evaluation of trophoblast cell surface antigen-2 (TROP2) protein expression in chemotherapy-resistant and metastatic breast carcinomas. Pathol Res Pract. 2024;264:155724. https:\/\/doi.org\/10.1016\/j.prp.2024.155724.","journal-title":"Pathol Res Pract"},{"key":"4203_CR19","doi-asserted-by":"publisher","first-page":"3205","DOI":"10.1200\/JCO.22.01063","volume":"40","author":"NL Henry","year":"2022","unstructured":"Henry NL, Somerfield MR, Dayao Z, Elias A, Kalinsky K, McShane LM, et al. Biomarkers for systemic therapy in metastatic breast cancer: ASCO guideline update. J Clin Oncol. 2022;40:3205\u201321. https:\/\/doi.org\/10.1200\/JCO.22.01063.","journal-title":"J Clin Oncol"},{"key":"4203_CR20","doi-asserted-by":"publisher","first-page":"4137","DOI":"10.3390\/cancers14174137","volume":"14","author":"J \u0160vec","year":"2022","unstructured":"\u0160vec J, \u0160\u0165astn\u00e1 M, Jane\u010dkov\u00e1 L, Hr\u010dkul\u00e1k D, Vojt\u011bchov\u00e1 M, Onhajzer J, et al. TROP2 represents a negative prognostic factor in colorectal adenocarcinoma and its expression is associated with features of epithelial-mesenchymal transition and invasiveness. Cancers. 2022;14:4137. https:\/\/doi.org\/10.3390\/cancers14174137.","journal-title":"Cancers"},{"key":"4203_CR21","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1007\/s40291-016-0250-z","volume":"21","author":"F Jia","year":"2017","unstructured":"Jia F, Teer JK, Knepper TC, Lee JK, Zhou H-H, He Y-J, et al. Discordance of somatic mutations between Asian and Caucasian patient populations with gastric cancer. Mol Diagn Ther. 2017;21:179\u201385. https:\/\/doi.org\/10.1007\/s40291-016-0250-z.","journal-title":"Mol Diagn Ther"},{"key":"4203_CR22","doi-asserted-by":"publisher","first-page":"391","DOI":"10.5230\/jgc.2024.24.e32","volume":"24","author":"HS Kim","year":"2024","unstructured":"Kim HS, Kim Y, Lee HS. Clinicopathologic characteristics of Trop family proteins (Trop-2 and EpCAM) in gastric carcinoma. J Gastric Cancer. 2024;24:391\u2013405. https:\/\/doi.org\/10.5230\/jgc.2024.24.e32.","journal-title":"J Gastric Cancer"}],"container-title":["Clinical and Translational Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12094-025-04203-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12094-025-04203-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12094-025-04203-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T12:57:29Z","timestamp":1781873849000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12094-025-04203-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,14]]},"references-count":22,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2026,7]]}},"alternative-id":["4203"],"URL":"https:\/\/doi.org\/10.1007\/s12094-025-04203-6","relation":{},"ISSN":["1699-3055"],"issn-type":[{"value":"1699-3055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,14]]},"assertion":[{"value":"2 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The author(s) declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This study was approved by the Institutional Review Board of the Charit\u00e9 (EA4\/115\/10).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Retrospective study, so no consent of participation is possible.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Retrospective study, so no consent of participation is possible.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}]}}